WEBVTT
Kind: captions
Language: en

00:00:00.000 --> 00:00:03.169 

for<00:00:00.750> families<00:00:01.380> served<00:00:01.800> by<00:00:02.010> MDA<00:00:02.399> the<00:00:02.939> Jerry

00:00:03.169 --> 00:00:03.179 
for families served by MDA the Jerry

00:00:03.179 --> 00:00:06.230 
for families served by MDA the Jerry
Lewis<00:00:03.330> telethon<00:00:03.510> is<00:00:04.259> a<00:00:04.440> source<00:00:04.859> of<00:00:05.069> hope<00:00:05.279> hope

00:00:06.230 --> 00:00:06.240 
Lewis telethon is a source of hope hope

00:00:06.240 --> 00:00:08.330 
Lewis telethon is a source of hope hope
that<00:00:06.270> scientific<00:00:07.200> and<00:00:07.379> medical<00:00:07.560> answers<00:00:08.160> will

00:00:08.330 --> 00:00:08.340 
that scientific and medical answers will

00:00:08.340 --> 00:00:10.430 
that scientific and medical answers will
be<00:00:08.460> found<00:00:08.760> to<00:00:09.059> defeat<00:00:09.510> more<00:00:09.780> than<00:00:09.960> 40

00:00:10.430 --> 00:00:10.440 
be found to defeat more than 40

00:00:10.440 --> 00:00:12.520 
be found to defeat more than 40
progressive<00:00:11.130> often<00:00:11.820> life-threatening

00:00:12.520 --> 00:00:12.530 
progressive often life-threatening

00:00:12.530 --> 00:00:15.860 
progressive often life-threatening
neuromuscular<00:00:13.530> diseases<00:00:13.940> for<00:00:14.940> decades<00:00:15.120> MDA

00:00:15.860 --> 00:00:15.870 
neuromuscular diseases for decades MDA

00:00:15.870 --> 00:00:17.630 
neuromuscular diseases for decades MDA
has<00:00:16.199> fostered<00:00:16.440> scientific<00:00:17.369> and<00:00:17.520> clinical

00:00:17.630 --> 00:00:17.640 
has fostered scientific and clinical

00:00:17.640 --> 00:00:19.760 
has fostered scientific and clinical
studies<00:00:18.300> at<00:00:18.510> leading<00:00:18.840> institutions<00:00:19.619> around

00:00:19.760 --> 00:00:19.770 
studies at leading institutions around

00:00:19.770 --> 00:00:21.470 
studies at leading institutions around
the<00:00:20.039> world<00:00:20.310> with<00:00:20.789> the<00:00:20.910> goal<00:00:21.119> of<00:00:21.150> developing

00:00:21.470 --> 00:00:21.480 
the world with the goal of developing

00:00:21.480 --> 00:00:23.720 
the world with the goal of developing
effective<00:00:22.170> therapies<00:00:22.890> for<00:00:22.920> all<00:00:23.340> of<00:00:23.609> the

00:00:23.720 --> 00:00:23.730 
effective therapies for all of the

00:00:23.730 --> 00:00:27.050 
effective therapies for all of the
diseases<00:00:24.269> in<00:00:24.449> mda's<00:00:25.050> program<00:00:26.000> this<00:00:27.000> year

00:00:27.050 --> 00:00:27.060 
diseases in mda's program this year

00:00:27.060 --> 00:00:30.019 
diseases in mda's program this year
mda's<00:00:27.930> Auggie's<00:00:28.529> quest<00:00:28.920> research<00:00:29.429> initiative

00:00:30.019 --> 00:00:30.029 
mda's Auggie's quest research initiative

00:00:30.029 --> 00:00:32.749 
mda's Auggie's quest research initiative
launched<00:00:30.750> an<00:00:30.840> extraordinary<00:00:31.430> ALS<00:00:32.430> drug

00:00:32.749 --> 00:00:32.759 
launched an extraordinary ALS drug

00:00:32.759 --> 00:00:34.880 
launched an extraordinary ALS drug
discovery<00:00:33.329> project<00:00:33.630> in<00:00:34.140> partnership<00:00:34.860> with

00:00:34.880 --> 00:00:34.890 
discovery project in partnership with

00:00:34.890 --> 00:00:37.760 
discovery project in partnership with
ALS<00:00:35.730> therapy<00:00:36.360> Development<00:00:36.960> Institute<00:00:37.140> in

00:00:37.760 --> 00:00:37.770 
ALS therapy Development Institute in

00:00:37.770 --> 00:00:40.610 
ALS therapy Development Institute in
Massachusetts<00:00:38.520> the<00:00:39.329> project<00:00:39.840> is<00:00:39.989> seeking<00:00:40.350> new

00:00:40.610 --> 00:00:40.620 
Massachusetts the project is seeking new

00:00:40.620 --> 00:00:42.860 
Massachusetts the project is seeking new
genetic<00:00:41.190> signposts<00:00:41.940> that<00:00:42.329> will<00:00:42.480> point<00:00:42.690> the

00:00:42.860 --> 00:00:42.870 
genetic signposts that will point the

00:00:42.870 --> 00:00:44.750 
genetic signposts that will point the
way<00:00:42.899> toward<00:00:43.079> treatment<00:00:43.829> possibilities<00:00:44.550> in

00:00:44.750 --> 00:00:44.760 
way toward treatment possibilities in

00:00:44.760 --> 00:00:48.440 
way toward treatment possibilities in
ALS<00:00:45.300> Lou<00:00:45.809> Gehrig's<00:00:46.200> disease<00:00:46.700> MDA<00:00:47.700> is<00:00:48.030> also

00:00:48.440 --> 00:00:48.450 
ALS Lou Gehrig's disease MDA is also

00:00:48.450 --> 00:00:50.990 
ALS Lou Gehrig's disease MDA is also
collaborating<00:00:49.110> with<00:00:49.140> ptc<00:00:49.800> therapeutics<00:00:50.280> in

00:00:50.990 --> 00:00:51.000 
collaborating with ptc therapeutics in

00:00:51.000 --> 00:00:54.650 
collaborating with ptc therapeutics in
new<00:00:51.120> jersey<00:00:51.149> a<00:00:51.660> substance<00:00:52.530> known<00:00:52.770> as<00:00:52.800> PTC<00:00:53.730> 124

00:00:54.650 --> 00:00:54.660 
new jersey a substance known as PTC 124

00:00:54.660 --> 00:00:57.020 
new jersey a substance known as PTC 124
is<00:00:55.170> undergoing<00:00:55.649> clinical<00:00:55.920> testing<00:00:56.640> to

00:00:57.020 --> 00:00:57.030 
is undergoing clinical testing to

00:00:57.030 --> 00:00:59.150 
is undergoing clinical testing to
determine<00:00:57.329> its<00:00:57.629> ability<00:00:58.050> to<00:00:58.079> avert<00:00:58.620> severe

00:00:59.150 --> 00:00:59.160 
determine its ability to avert severe

00:00:59.160 --> 00:01:01.729 
determine its ability to avert severe
muscle<00:00:59.460> wasting<00:01:00.030> in<00:01:00.149> many<00:01:00.660> cases<00:01:00.899> of<00:01:01.289> Duchenne

00:01:01.729 --> 00:01:01.739 
muscle wasting in many cases of Duchenne

00:01:01.739 --> 00:01:05.660 
muscle wasting in many cases of Duchenne
muscular<00:01:01.770> dystrophy<00:01:03.890> Duchene<00:01:04.890> continues<00:01:05.519> to

00:01:05.660 --> 00:01:05.670 
muscular dystrophy Duchene continues to

00:01:05.670 --> 00:01:08.300 
muscular dystrophy Duchene continues to
be<00:01:05.760> the<00:01:05.909> subject<00:01:06.150> of<00:01:06.450> a<00:01:06.540> historic<00:01:06.930> MDA<00:01:07.619> funded

00:01:08.300 --> 00:01:08.310 
be the subject of a historic MDA funded

00:01:08.310 --> 00:01:10.760 
be the subject of a historic MDA funded
gene<00:01:08.549> therapy<00:01:09.060> trial<00:01:09.360> underway<00:01:10.140> with<00:01:10.530> help

00:01:10.760 --> 00:01:10.770 
gene therapy trial underway with help

00:01:10.770 --> 00:01:13.010 
gene therapy trial underway with help
from<00:01:10.979> Asclepius<00:01:11.840> biopharmaceuticals<00:01:12.840> in

00:01:13.010 --> 00:01:13.020 
from Asclepius biopharmaceuticals in

00:01:13.020 --> 00:01:15.289 
from Asclepius biopharmaceuticals in
North<00:01:13.260> Carolina<00:01:13.439> and<00:01:13.979> Children's<00:01:14.760> Hospital

00:01:15.289 --> 00:01:15.299 
North Carolina and Children's Hospital

00:01:15.299 --> 00:01:18.109 
North Carolina and Children's Hospital
in<00:01:15.450> Columbus<00:01:15.900> Ohio<00:01:16.340> following<00:01:17.340> analysis<00:01:17.610> of

00:01:18.109 --> 00:01:18.119 
in Columbus Ohio following analysis of

00:01:18.119 --> 00:01:20.240 
in Columbus Ohio following analysis of
data<00:01:18.270> from<00:01:18.659> the<00:01:18.780> initial<00:01:19.049> safety<00:01:19.680> study<00:01:19.979> done

00:01:20.240 --> 00:01:20.250 
data from the initial safety study done

00:01:20.250 --> 00:01:23.179 
data from the initial safety study done
in<00:01:20.280> affected<00:01:20.939> boys<00:01:21.150> this<00:01:21.869> gene<00:01:22.320> therapy<00:01:22.890> trial

00:01:23.179 --> 00:01:23.189 
in affected boys this gene therapy trial

00:01:23.189 --> 00:01:25.460 
in affected boys this gene therapy trial
is<00:01:23.549> poised<00:01:24.000> to<00:01:24.210> move<00:01:24.360> on<00:01:24.540> to<00:01:24.720> a<00:01:24.750> significant

00:01:25.460 --> 00:01:25.470 
is poised to move on to a significant

00:01:25.470 --> 00:01:29.359 
is poised to move on to a significant
new<00:01:25.710> face<00:01:26.040> with<00:01:26.610> more<00:01:26.850> results<00:01:27.299> to<00:01:27.420> come<00:01:27.630> and<00:01:28.369> a

00:01:29.359 --> 00:01:29.369 
new face with more results to come and a

00:01:29.369 --> 00:01:31.730 
new face with more results to come and a
disorder<00:01:29.909> that<00:01:30.030> formerly<00:01:30.570> was<00:01:30.750> almost<00:01:31.140> always

00:01:31.730 --> 00:01:31.740 
disorder that formerly was almost always

00:01:31.740 --> 00:01:34.640 
disorder that formerly was almost always
fatal<00:01:32.040> in<00:01:32.369> young<00:01:32.549> children<00:01:33.020> infantile<00:01:34.020> onset

00:01:34.640 --> 00:01:34.650 
fatal in young children infantile onset

00:01:34.650 --> 00:01:37.670 
fatal in young children infantile onset
pompe<00:01:35.189> disease<00:01:35.420> can<00:01:36.420> now<00:01:36.630> be<00:01:36.869> successfully

00:01:37.670 --> 00:01:37.680 
pompe disease can now be successfully

00:01:37.680 --> 00:01:40.460 
pompe disease can now be successfully
treated<00:01:37.710> thanks<00:01:38.640> to<00:01:38.759> a<00:01:38.790> drug<00:01:39.180> miles<00:01:39.869> on<00:01:40.229> that

00:01:40.460 --> 00:01:40.470 
treated thanks to a drug miles on that

00:01:40.470 --> 00:01:43.069 
treated thanks to a drug miles on that
was<00:01:40.979> granted<00:01:41.369> FDA<00:01:41.700> approval<00:01:42.360> last<00:01:42.540> year<00:01:42.869> and

00:01:43.069 --> 00:01:43.079 
was granted FDA approval last year and

00:01:43.079 --> 00:01:45.889 
was granted FDA approval last year and
developed<00:01:43.860> with<00:01:44.040> MDA<00:01:44.399> support<00:01:45.030> wives<00:01:45.630> are

00:01:45.889 --> 00:01:45.899 
developed with MDA support wives are

00:01:45.899 --> 00:01:48.289 
developed with MDA support wives are
being<00:01:46.049> saved<00:01:46.770> thanks<00:01:47.729> to<00:01:47.759> the<00:01:47.880> first

00:01:48.289 --> 00:01:48.299 
being saved thanks to the first

00:01:48.299 --> 00:01:50.420 
being saved thanks to the first
definitive<00:01:48.899> treatment<00:01:49.439> for<00:01:49.979> a<00:01:50.009> genetic

00:01:50.420 --> 00:01:50.430 
definitive treatment for a genetic

00:01:50.430 --> 00:01:53.719 
definitive treatment for a genetic
disorder<00:01:50.759> in<00:01:51.479> mda's<00:01:52.020> program<00:01:52.560> make<00:01:53.549> your

00:01:53.719 --> 00:01:53.729 
disorder in mda's program make your

00:01:53.729 --> 00:01:55.880 
disorder in mda's program make your
contribution<00:01:54.509> now<00:01:54.720> to<00:01:55.079> support<00:01:55.470> MDA

00:01:55.880 --> 00:01:55.890 
contribution now to support MDA

00:01:55.890 --> 00:01:59.389 
contribution now to support MDA
scientific<00:01:56.729> and<00:01:56.909> clinical<00:01:57.000> research<00:01:58.399> MDA

00:01:59.389 --> 00:01:59.399 
scientific and clinical research MDA

00:01:59.399 --> 00:02:02.270 
scientific and clinical research MDA
research<00:01:59.909> means<00:02:00.329> real<00:02:00.840> progress<00:02:01.290> and<00:02:01.680> a<00:02:01.979> real

00:02:02.270 --> 00:02:02.280 
research means real progress and a real

00:02:02.280 --> 00:02:03.620 
research means real progress and a real
reason<00:02:02.640> for<00:02:02.880> hope

00:02:03.620 --> 00:02:03.630 
reason for hope

00:02:03.630 --> 00:02:06.289 
reason for hope
that<00:02:03.840> neuromuscular<00:02:04.710> diseases<00:02:05.100> will<00:02:05.640> soon<00:02:06.030> be

00:02:06.289 --> 00:02:06.299 
that neuromuscular diseases will soon be

00:02:06.299 --> 00:02:09.920 
that neuromuscular diseases will soon be
defeated<00:02:06.899> in<00:02:07.079> our<00:02:07.590> time

